Molecular cytogenetic monitoring from CD34+ peripheral blood cells in myelodysplastic syndromes: first results from a prospective multicenter German diagnostic study

Leuk Res. 2013 Aug;37(8):900-6. doi: 10.1016/j.leukres.2013.03.019. Epub 2013 Apr 25.

Abstract

The gold standard of cytogenetic analysis in myelodysplastic syndromes (MDS) is conventional chromosome banding (CCB) analysis of bone marrow (BM) metaphases. Most aberrations can also be detected by fluorescence-in situ-hybridization (FISH). For this prospective multicenter German diagnostic study (www.clinicaltrials.gov: #NCT01355913) 360 patients, as yet, were followed up to 3 years by sequential FISH analyses of immunomagnetically enriched CD34+ peripheral blood (PB) cells using comprehensive FISH probe panels, resulting in a total number of 19,516 FISH analyses. We demonstrate that CD34+ PB FISH correlates significantly with CCB analysis and represents a feasible method for a reliable non-invasive cytogenetic monitoring from PB.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, CD34 / blood
  • Antigens, CD34 / metabolism*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Azacitidine / administration & dosage
  • Azacitidine / therapeutic use
  • Chromosome Aberrations / drug effects
  • Chromosome Banding / methods*
  • Female
  • Follow-Up Studies
  • Germany
  • Humans
  • In Situ Hybridization, Fluorescence / methods*
  • Lenalidomide
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / blood
  • Myelodysplastic Syndromes / drug therapy
  • Myelodysplastic Syndromes / genetics*
  • Prospective Studies
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives
  • Thalidomide / therapeutic use
  • Time Factors
  • Treatment Outcome

Substances

  • Antigens, CD34
  • Thalidomide
  • Lenalidomide
  • Azacitidine

Associated data

  • ClinicalTrials.gov/NCT01355913